 ADAMTS13 Protein
"ADAMTS13 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ADAMTS protease that contains eight thrombospondin (TS) motifs. It cleaves VON WILLEBRAND FACTOR to control vWF-mediated THROMBOSIS. Mutations in the ADAMTS13 gene have been identified in familial cases of PURPURA, THROMBOTIC THROMBOCYTOPENIC and defects in ADAMTS13 activity are associated with MYOCARDIAL INFARCTION; BRAIN ISCHEMIA; PRE-ECLAMPSIA; and MALARIA.
| Descriptor ID |
D000071120
|
| MeSH Number(s) |
D08.811.277.656.675.374.102.500.813 D09.400.430.500.500.813 D12.776.395.033.500.813 D12.776.860.300.085.813
|
| Concept/Terms |
ADAMTS13 Protein- ADAMTS13 Protein
- von Willebrand Factor-Cleaving Protease
- von Willebrand Factor Cleaving Protease
- ADAMTS13 Protease
- vWF-Cleaving Protease
- vWF Cleaving Protease
- ADAMTS-13 Protein
- ADAMTS 13 Protein
- A Disintegrin and Metalloproteinase with Thrombospondin Motifs 13 Protein
|
Below are MeSH descriptors whose meaning is more general than "ADAMTS13 Protein".
Below are MeSH descriptors whose meaning is more specific than "ADAMTS13 Protein".
This graph shows the total number of publications written about "ADAMTS13 Protein" by people in this website by year, and whether "ADAMTS13 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2017 | 1 | 1 | 2 | | 2019 | 1 | 2 | 3 | | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "ADAMTS13 Protein" by people in Profiles.
-
Scully M, de la Rubia J, Pavenski K, Metjian A, Kn?bl P, Peyvandi F, Cataland S, Coppo P, Kremer Hovinga JA, Minkue Mi Edou J, De Passos Sousa R, Callewaert F, Gunawardena S, Lin J. Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study. J Thromb Haemost. 2022 12; 20(12):2810-2822.
-
Chaturvedi S, Antun AG, Farland AM, Woods R, Metjian A, Park YA, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sadler JE, Sridharan M, Go RS, McCrae KR, Upreti HV, Liu A, Lim MY, Gangaraju R, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson A, Davis E, Evans MD, Mazepa MA. Race, rituximab, and relapse in TTP. Blood. 2022 09 22; 140(12):1335-1344.
-
Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2020 02; 18(2):479-484.
-
Bortot M, Ashworth K, Sharifi A, Walker F, Crawford NC, Neeves KB, Bark D, Di Paola J. Turbulent Flow Promotes Cleavage of VWF (von Willebrand Factor) by ADAMTS13 (A Disintegrin and Metalloproteinase With a Thrombospondin Type-1 Motif, Member 13). Arterioscler Thromb Vasc Biol. 2019 09; 39(9):1831-1842.
-
Scully M, Cataland SR, Peyvandi F, Coppo P, Kn?bl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019 01 24; 380(4):335-346.
-
Tanhehco YC, Arepally G, Metjian A. Novel therapeutic approaches for thrombotic thrombocytopenic purpura. Curr Opin Hematol. 2017 Nov; 24(6):521-528.
-
Bendapudi PK, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, Sun L, Upadhyay V, Hamdan A, Brunner AM, Gansner JM, Viswanathan S, Kaufman RM, Uhl L, Stowell CP, Dzik WH, Makar RS. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017 Apr; 4(4):e157-e164.
-
Wu TC, Yang S, Haven S, Holers VM, Lundberg AS, Wu H, Cataland SR. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2013 Oct; 11(10):1925-7.
-
Lambers M, Goldenberg NA, Kenet G, Kirkham FJ, Manner D, Bernard T, Mesters RM, Junker R, Stoll M, Nowak-G?ttl U. Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study. Ann Neurol. 2013 Jan; 73(1):58-64.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|